Ruxolitinib tablets/Jekwei combination regimen

Ruxolitinib tablets/Ruxolitinib (Ruxolitinib), as a JAK inhibitor, is mainly used to treat diseases such as myelofibrosis, polycythemia vera and graft-versus-host disease. With further research on this drug, more and more treatment options are beginning to adopt combination drug strategies, aiming to improve the therapeutic effect, reduce side effects, or deal with different types of clinical symptoms.

First, the combination of ruxolitinib and corticosteroids has become a common combination regimen, especially in the treatment of graft-versus-host disease (GVHD). Corticosteroids (such as prednisone) are usually used to reduce inflammatory responses, while ruxolitinib regulates the immune system and slows the progression of GVHD by inhibiting the JAK-STAT signaling pathway. In the early stage of treatment, a combination of corticosteroids and ruxolitinib is usually used. As the disease is controlled and stabilized, doctors will gradually reduce the use of corticosteroids and switch to only ruxolitinib.

In addition, the combination of ruxolitinib and chemotherapy drugs has also been successful in the treatment of certain diseases. For example, in the treatment of certain types of myelofibrosis, ruxolitinib can be used in combination with chemotherapy drugs (such as cyclophosphamide) to enhance the anti-tumor effect. By combining drugs, the proliferation of tumor cells can be further reduced and the success rate of treatment can be improved.

For polycythemia vera, ruxolitinib is sometimes given in combination with low-dose aspirin. Aspirin helps prevent thrombosis through its antiplatelet effect, while ruxolitinib reduces the overproduction of red blood cells by regulating the JAK-STAT signaling pathway. The combined use of the two can effectively reduce the risk of thrombotic events and improve the clinical performance of patients.

However, the choice of combination regimen needs to be determined based on the patient's specific condition, drug resistance, and side effect tolerance. When choosing combination therapy, physicians will consider the interactions of different drugs, the patient's drug tolerance, and clinical response.

Reference materials:https://www.jakavi.com/